Last reviewed · How we verify
Combination product: Trastuzumab + Pertuzumab (combination-product-trastuzumab-pertuzumab)
Trastuzumab and pertuzumab target HER2, blocking signal transduction pathways that promote tumor growth and survival.
At a glance
| Generic name | combination-product-trastuzumab-pertuzumab |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 3 |
Mechanism of action
This combination therapy works by using two different monoclonal antibodies to bind to the HER2 receptor, which helps prevent cancer cells from growing and dividing. By targeting HER2 from multiple angles, the drugs enhance the inhibition of the HER2 signaling pathway.
Approved indications
Common side effects
- Diarrhoea
- Alopecia
- Nausea
- Fatigue
- Asthenia
- Anaemia
- Rash
- Vomiting
- Arthralgia
- Headache
- Neuropathy peripheral
- Pruritus
Key clinical trials
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (PHASE3)
- Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (PHASE1)
- A Study of Surgery and Radiotherapy in People With Breast Cancer (PHASE2)
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (PHASE1, PHASE2)
- Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: